If you are on the fence about what to do with your GSK shares, you are not alone. The stock has seen some interesting moves ...

GlaxoSmithKline ( ($GB:GSK) ) has issued an update. GSK plc announced the acquisition of ordinary shares by several key executives, including the ...

Emma Walmsley has overseen eight turbulent years at he U.K. drugmaker. The firm announced Monday that she will be succeeded by GSK insider and drug industry stalwart Luke Miels.

GSK plc’s strong oncology growth, highlighted by Ojjaara sales and an upgraded 2025 outlook, earns a continued 'Buy' rating.

Unlike peers, GSK plc faces limited Loss of Exclusivity risk, supporting steady revenue projections and justifying higher ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026. Luke will succeed the current CEO, Dame Emma ...

GSK announced that Luke Miels, the company’s chief commercial officer, will take over as CEO on Jan. 1, replacing Emma ...

CEO Emma Walmsley said GSK has had a minimal role in an effort by the FDA to update the prescribing information of the ...

GSK plc GSK is one of the key vaccine makers in the world, marketing vaccines to help prevent infectious diseases like Respiratory Syncytial Virus or RSV, meningitis, shingles, hepatitis and many more ...